FAK in cancer: mechanistic findings and clinical applications.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 25098269.
- Also identified by DOI 10.1038/nrc3792 and PMC identifier 4365862.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Focal adhesion kinase (FAK) is a cytoplasmic protein tyrosine kinase that is overexpressed and activated in several advanced-stage solid cancers. FAK promotes tumour progression and metastasis through effects on cancer cells, as well as stromal cells of the tumour microenvironment. The kinase-dependent and kinase-independent functions of FAK control cell movement, invasion, survival, gene expression and cancer stem cell self-renewal. Small molecule FAK inhibitors decrease tumour growth and metastasis in several preclinical models and have initial clinical activity in patients with limited adverse events. In this Review, we discuss FAK signalling effects on both tumour and stromal cell biology that provide rationale and support for future therapeutic opportunities.
Medical subject headings
- Focal Adhesion Kinase 1
- Neoplasms
- Protein Kinase Inhibitors
- Stromal Cells